Related Experiment Videos

Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis

William L Baker1, Kimberly A Couch

  • 1School of Pharmacy, University of Connecticut, Storrs, and Division of Cardiology, Hartford Hospital 06102, USA. wbaker01@harthosp.org

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|April 11, 2007
PubMed

Insights

Azithromycin does not significantly reduce recurrent cardiac events in patients with coronary artery disease (CAD). Further trials are needed to clarify its role in secondary prevention of cardiovascular events.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Coronary artery disease (CAD) is a leading cause of mortality worldwide.
  • Secondary prevention strategies aim to reduce recurrent cardiovascular events in patients with established CAD.
  • The role of anti-inflammatory agents, including macrolide antibiotics like azithromycin, is being investigated for secondary CAD prevention.

Purpose of the Study:

  • To evaluate the effect of azithromycin on clinical outcomes in patients with coronary artery disease (CAD).
  • To conduct a meta-analysis of randomized, controlled trials (RCTs) assessing azithromycin's impact on mortality and cardiac events in CAD patients.

Main Methods:

  • Systematic literature search of major databases (MEDLINE, EMBASE, Web of Science, Cochrane).
  • Inclusion of RCTs comparing azithromycin with placebo in secondary CAD patients.
  • Random-effects model used for meta-analysis of mortality and clinical cardiac endpoints.

Main Results:

  • Six studies (n=13,778) met inclusion criteria.
  • Azithromycin showed a nonsignificant reduction in mortality (OR, 0.91; 95% CI, 0.77-1.09).
  • No significant effect observed for nonfatal myocardial infarction, hospitalization rates, or composite cardiovascular endpoints.

Conclusions:

  • Azithromycin does not appear to reduce the frequency of recurrent cardiac events in patients with CAD.
  • Current evidence does not support the use of azithromycin for secondary prevention in CAD.
  • Ongoing trials may further elucidate the potential role of azithromycin in cardiovascular disease management.
Abstract

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...